Penningtons Manches Cooper advises Cryogatt Systems Limited on sale of patent portfolio to TMRW Life Sciences

Posted: 16/06/2025

The corporate team at Penningtons Manches cooper has advised Cryogatt Systems Limited, a biotechnology company specialising in cryogenic radio frequency identification (RFID) technology on the sale of its patent portfolio to New York-based TMRW Life Sciences, a fertility technology company focused on egg and embryo storage.

Prior to the acquisition of its patent portfolio, Cryogatt, based in Hertfordshire, UK, was the sole provider of patented cryogenic RFID technology. RIFD technology uses radio waves to identify a tagged object. Cryogatt previously used this technology to revolutionise sample tracking in biotechnology, healthcare and research.

TMRW Life Sciences is a fertility technology company based in New York with a goal of transforming the egg and embryo storage space. It uses state of the art technology to identify, track and remotely monitor frozen eggs and embryos – the purchase of the RFID technology boosts its offering.

The Penningtons Manches Cooper team, led by Global Head of Corporate, Matthew Martin, with support from associate Emily MacDonald, advised on the legal aspects of this deal for Cryogatt, represented by its joint liquidators Laurence Pagden and Giuseppe Parla of Menzies LLP.

Cynthia Hudson, Head of Clinical Strategy at TMRW Life Sciences believes that these patents will "help lay the foundation for the next generation of TMRW's digital solutions" and aid in the expansion of their product offering to "support each fertility clinic's unique needs".

Louis Villalba, CEO of TMRW Life Sciences added that the acquisition "reflects our commitment to continued innovation and to supporting clinics with technology that goes beyond what's required today."

Matthew Martin said: "We are delighted to have been a part of this deal and to have worked with such an innovative company in Cryogatt. We're eager to see how this new biotechnology impacts the fertility industry and the life science industry as a whole."

Return to news headlines